59 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51.
Max Planck Institute of Psychiatry
Applications of Fluorine in Medicinal Chemistry.
Bristol-Myers Squibb Research and Development
Structure-Affinity Relationship Analysis of Selective FKBP51 Ligands.
Max Planck Institute of Psychiatry
Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control.
Max Institute of Psychiatry
Structure-based design of novel, urea-containing FKBP12 inhibitors.
Agouron Pharmaceuticals
High-affinity FKBP-12 ligands derived from (R)-()-carvone. Synthesis and evaluation of FK506 pyranose ring replacements
TBA
Synopsis of some recent tactical application of bioisosteres in drug design.
Bristol-Myers Squibb Pharmaceutical Research and Development
Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52.
Max Planck Institute of Psychiatry
Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52.
Max Planck Institute of Psychiatry
Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP protein.
University of Wu£Rzburg
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
The Scripps Research Institute
Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity.
Novartis Pharma
Design, synthesis and X-ray crystallographic studies of [7.3.1] and [8.3.1] macrocyclic FKBP-12 ligands
TBA
Preparation and in vitro activities of naphthyl and indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin
TBA
Alkyl ether derivatives of the FK-506 related, immunosuppressive macrolide L-683,742 (C31-O-desmethyl ascomycin)
TBA
The contribution to binding of the pyranoside substituents in the excised binding domain of FK-506
TBA
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
University of California San Diego
Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties.
Biocon Bristol-Myers Squibb R&D Centre
Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.
University of Michigan
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation.
Second Military Medical University (Naval Medical University)
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).
University of Hradec Kralove
Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.
Technical University Darmstadt
Regulation of gene expression by synthetic dimerizers with novel specificity.
Ariad Gene Therapeutics
Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria.
University of W£Rzburg
Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress.
Universidad Del Pa£S Vasco Upv/Ehu
Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.
Guilford Pharmaceuticals
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.
Guilford Pharmaceuticals
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.
Guilford Pharmaceuticals
Antifungal rapamycin analogues with reduced immunosuppressive activity.
Abbott Laboratories
Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay.
Bristol-Myers Squibb Pharmaceutical Research Institute
Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket.
Ariad Gene Therapeutics
Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.
Abbott Laboratories
Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties.
Max-Planck Research Unit
Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity.
Merck Research Laboratories
C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.
Merck Research Laboratories
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Bristol-Myers Squibb
C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.
Merck Research Laboratories
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Eberhard Karls University T£Bingen
Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations.
Yale University
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
Abbott Laboratories
Chemogenomic Profiling of Human and Microbial FK506-Binding Proteins.
Max Planck Institute of Psychiatry
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
Arbutus Biopharma
Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof
Pharmablock Sciences (Nanjing)
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
University of Illinois At Chicago